BioVie announced statistically significant positive results from its Phase 2 ADDRESS-LC trial for bezisterim in Long COVID patients, particularly in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise. This represents a major positive catalyst for the company, as there are currently no FDA-approved treatments for Long COVID, a condition affecting millions.
BioVie has announced positive topline results from its Phase 2 ADDRESS-LC trial for bezisterim, an investigational drug for Long COVID. The filing highlights statistically significant benefits observed in bezisterim-treated patients, especially in subgroups with high baseline fatigue, cognitive impairment, and post-exertional malaise. This is a significant development because Long COVID affects an estimated 17-20 million U.S. adults with no FDA-approved treatment options, creating a substantial unmet medical need. For BioVie, this positive data could pave the way for further clinical development and potential market entry, representing a major short-term opportunity for the stock. Long-term implications depend on successful progression through Phase 3 trials and regulatory approval, but this initial success significantly de-risks the drug candidate and positions BioVie favorably in a large, underserved market.